Table 3.
Mann–Whitney 3‐year survivors versus no survivors.
| Proteins (AU) | Survival ≤ 3 years | Survival < 3 years | p Value |
|---|---|---|---|
| ANXA1 | 3.3 (2.6–3.8) | 4.3 (3–5) | 0.0132* |
| Azurocidin | 3.3 (2.4–4.7) | 4.5 (3.2–5.8) | 0.0772 |
| CASP‐3 | 230.8 (152.4–581.4) | 310 (148.1–784.6) | 0.4332 |
| CCL15 | 91.9 (81.5–113.8) | 108.1 (91.4–157.7) | 0.1301 |
| CCL3 | 6.3 (5.3–7.9) | 5.2 (4.6–8.2) | 0.7575 |
| CD4 | 19.1 (14.5–24.4) | 18.8 (16.5–26.2) | 0.4579 |
| CD70 | 11.4 (9.2–17.2) | 12.4 (10.1–15.2) | 0.6804 |
| CEACAM8 | 11.9 (9.8–20.4) | 19.6 (15.3–25.8) | 0.0225* |
| CHI3L1 | 42.9 (36.8–59) | 56.6 (44.1–75.8) | 0.0581 |
| CHIT1 | 4.2 (2.3–6.6) | 6 (3.9–6.9) | 0.207 |
| CXCL13 | 598.7 (421.6–1145) | 449.6 (347.7–816.6) | 0.1853 |
| CXCL17 | 36.8 (32–42.6) | 45.9 (38.9–57.1) | 0.0074* |
| FCRLB | 2.9 (2–3.7) | 3.6 (2.9–4.8) | 0.0581 |
| GDF‐15 | 29.9 (20.1–43.5) | 46.9 (31.3–58.4) | 0.011* |
| GPNMB | 56.6 (52.8–61.9) | 56.6 (52.3–64) | 0.9017 |
| IL‐17D | 5.7 (5–6.7) | 6.4 (5.4–7.2) | 0.3424 |
| IL‐1ra | 17.8 (14.7–31.8) | 20.4 (14.6–31.7) | 0.4212 |
| IL‐1RT2 | 17.9 (15.2–22.1) | 17.8 (13.6–20.3) | 0.6956 |
| IL‐4RA | 6.6 (5.3–11.8) | 8 (6.1–10.3) | 0.5501 |
| IL‐6 | 7.1 (5.3–14) | 13.4 (7.8–31.4) | 0.0388* |
| IL16 | 34.5 (25.1–54.4) | 38 (31.6–54.6) | 0.4455 |
| IL27 | 18.7 (15.3–22.4) | 21.6 (17.4–25.5) | 0.0808 |
| KIM‐1 | 549.9 (312.7–770.5) | 489.7 (269.8–830.5) | 0.8692 |
| MCP‐1 | 6.2 (5.3–7.6) | 7.1 (5.4–7.9) | 0.3116 |
| Osteoprotegerin | 7 (5.3–9.2) | 8 (6.8–9) | 0.5229 |
| PGLYRP1 | 110.4 (75.4–146.7) | 117.5 (96.7–153.1) | 0.3217 |
| PIgR | 55.3 (50.1–58.4) | 54 (51.1–59.4) | 0.8854 |
| PSP‐D | 6.3 (3.3–9.3) | 9.9 (6–14.9) | 0.0266* |
| PTX3‐log | 9.2 (7.7–11.6) | 10 (8.8–12.5) | 0.1529 |
| SELE | 4.5 (2.8–5.6) | 4.6 (3.6–5.7) | 0.5229 |
| SLAMF7 | 3.9 (2.4–5.1) | 4.6 (3.8–5.7) | 0.0872 |
| TNF‐R1 | 25 (19.2–33.1) | 33.9 (22.8–40.3) | 0.064 |
| TNF‐R2 | 18.9 (14.4–31.5) | 26 (18.9–30.6) | 0.2146 |
| TNFRSF10A (TRAIL‐R1) | 9.6 (7.1–12.6) | 10.7 (9.3–12.3) | 0.3319 |
| TNFRSF11A | 40.1 (30.1–60.1) | 43.4 (31.2–61.9) | 0.4706 |
| TNFRSF13B | 255 (200.7–326.5) | 256 (213.5–346) | 0.578 |
| TNFRSF14 | 21.4 (14.3–29.3) | 23.7 (17.4–30.6) | 0.5501 |
| TNFRSF19 | 14 (11.8–23.4) | 18.4 (14.1–24.3) | 0.1923 |
| TNFRSF4 | 11.5 (7.4–16.9) | 14.7 (8.4–19.1) | 0.2735 |
| TNFRSF6B | 26.4 (15.3–36.3) | 32.5 (21.4–45.4) | 0.159 |
| TNFSF13 | 306.5 (243.7–369.8) | 325.8 (277.7–394.5) | 0.2224 |
| TNFSF13B | 68.6 (50.1–78.1) | 71.5 (51–101.2) | 0.3116 |
| TRAIL‐R2 | 46.3 (35.2–59.5) | 60 (44.1–97.3) | 0.0297* |
| TRAIL | 113.9 (100.1–132.7) | 109.6 (95.7–136.4) | 0.6505 |
Note: Table of protein levels in patients surviving ≤3 years or >3 years compared with Mann–Whitney's tests. Protein levels presented in AU, median (25–75 quartiles). p < 0.05 considered significant are marked with *; bold.
Abbreviations: ANXA1, annexin A1; AU, arbitrary units; CASP‐3, caspase‐3; CCL, C–C motif chemokine; CD, cluster of differentiation; CEACAM8, carcinoembryonic antigen‐related cell adhesion molecule 8; CHIT1, chitotriosidase‐1; CHI3L1, chitinase‐3‐like protein 1; CXCL, C–X–C motif chemokine; FcRLB, Fc receptor‐like B; GDF‐15, growth/differentiation factor 15; GPNMB, transmembrane glycoprotein neuromedin‐B; IL, interleukin; IL.1ra, IL‐1 receptor antagonist protein; IL‐1RT2, IL‐1 receptor type 2; IL‐4R‐alpha, IL‐4 receptor subunit alpha; KIM‐1, kidney injury molecule 1; MCP‐1, monocyte chemotactic protein 1; Pglyrp1, peptidoglycan recognition protein 1; PIgR, polymeric immunoglobulin receptor; PSP‐D, pulmonary surfactant‐associated protein D; PTX3, pentraxin‐related protein; SELE, E‐selectin; SLAMF7, signaling lymphocytic activation molecule family member 7; TNF‐R, TNF receptor; TNFRSF, TNF receptor superfamily member; TNFSF, TNF ligand superfamily member; TRAIL, tumor necrosis factor‐related apoptosis‐inducing ligand; TRAIL‐R2, TRAIL receptor 2.